Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Why AbbVie Inc. Slumped 13% In September

8,085 views

Published on

Amid a widespread industry sell-off and in the wake of positive trial data from competitor Gilead Sciences, shares in AbbVie, Inc tumbled by 12.8% last months. AbbVie's under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them.

Published in: Healthcare
  • Hi there! Essay Help For Students | Discount 10% for your first order! - Check our website! https://vk.cc/80SakO
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Hello everyone i am so happy to share my testimony on how i was able to get back my husband around April 2016 with the help of Chief Dr. Lebo. My husband left me and my kid for over Eight Months and went on with another lady and i was unable to move on with my life because of the love i have for him. On one faithful day i saw a testimony on the internet on how Chief Dr. Lebo helped someone with love spell and so many other testimonies. Though i never believed it but i just had to try my faith which i did and i contacted him through his Email and he told me what i need to do and after 2days, i received a call from my husband asking for forgiveness to come back to him. It was all like a dream to me. I am so so happy now as we are back together again. All thanks to Chief Dr. Lebo and i will advice anyone in need of help to contact him via Contact number +27631394550 E-MAIL:- chief.dr.lebo1@gmail.com Website:- http://www.chiefdrlebo.com
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Why AbbVie Inc. Slumped 13% In September

  1. 1. Why Abbvie Inc. Slumped 13% In September
  2. 2. What: • The large cap biopharma company is investing heavily in R&D to offset risk tied to the looming patent expiration of Humira. – Humira generates more than $12 billion in annual sales. – Humira accounts for 63% of year-to-date revenue. • Expansion into hepatitis C offers billion dollar potential. – Competitor Gilead Sciences reports positive phase 3 data for its pan-genotype hepatitis C drug on September 21. • Shares dropped 12.8% in September. Source Juno Therapeutics
  3. 3. AbbVie Inc.
  4. 4. So what: • Humira is AbbVie’s top selling therapy. – Sales of $6.6 billion through the first six months of 2015. – Patent protection ends on Humira in 2016. • AbbVie launched Viekira Pak for hepatitis C in Q1 2015 – Viekira Pak Q2 sales tracking at an annualized $1.5 billion pace.
  5. 5. So what continued:
  6. 6. So what continued: • Gilead Sciences announces positive data for next-generation, pan-genotype hepatitis C therapy. – 99% overall cure rate, including 98% rate in genotype 1. • Could reduce demand for Viekira Pak in genotype 1 patients. – Robust efficacy across genotypes 1 to 6. • Could remove need for genotype testing. • Could outmaneuver AbbVie’s pan-genotype next generation therapy: ABT-493 + ABT-530.
  7. 7. Now what: • Humira patent risk looms, but efforts underway on next-generation autoimmune drugs. • ABT-494: Advancing into late stage trials by year end. – 82% of rheumatoid arthritis patients achieved a 20% or greater improvement in symptoms in phase 2 trials. – In anti-TNF (such as Humira) non-responders, 71% achieved a 20% or greater improvement. – Safety profile potentially better than Humira with most common adverse event being headache. – Oral dosing rather than injection dosing like Humira.
  8. 8. Now what continued: • Significant opportunity in oncology. – Acquired Pharmacyclics in May to get Imbruvica. • Fast growing drug with billion dollar annual sales potential. – Venetoclax potential regulatory filing by year end. • Relapsed/refractory CLL with 17p deletion genetic mutation. – Elotuzumab filed for approval. • Decision expected in February 2016. • Improved progression free survival when added to standard of care.
  9. 9. Now what continued: • Absent a Humira successor, significant risk remains. • Continue to monitor progress on oncology pipeline. • Look for insight into timeline for next-generation pan- genotype HCV therapies during Q3 EPS report. • Recent decline may offer opportunity if company can execute on its plan to overcome Humira risk. – Underweight in portfolios until clarity exists.
  10. 10. Leaked: The next billion-dollar iSecret

×